New Portfolio Company

May 14, 2019

Paradigm Diagnostics Announces the Addition of Industry Executive Mara Aspinall to the Board of Directors as Part of the Series B Extension Closing Totaling $15 Million


Phoenix, Arizona –  Paradigm Diagnostics, a leading precision medicine company focused on comprehensive cancer testing, announced the addition of Mara Aspinall, Managing Director of BlueStone Venture Partners, to the Board of Directors as part of the closing of Paradigm’s $15 million Series B fundraising. In addition to participation by the founding investors, Mesa Verde Venture Partners, New Science Ventures, and Prairie Ventures, Paradigm is pleased to welcome the addition of Gore Range Ventures, the Tech Coast Angels’ San Diego (TCA-SD), OSF HealthCare Ventures, and BlueStone Venture Partners bringing the final Series B raise to $15 million to help support the rapid commercialization of the flagship product, the Paradigm Cancer Diagnostic (PCDx)... READ MORE

​​​​​BlueStone News

December 11, 2019

BlueStone Managing Director Mara Aspinall named to 2019 Most Influential Corporate Directors List by WomenInc. Magazine


Brentwood, Tennessee –BlueStone Managing Director, Mara Aspinall, today was named to WomenInc. Magazine's 2019 Most Influential Corporate Directors list. Mara was named in the upcoming winter 2019 edition magazine and recognized for her public company board roles: Allscripts HealthcareSolutions, Inc., OraSure Technologies, Inc.


As a leading business magazine reporting on women's success and achievement, the WomenInc.'s Most Influential Corporate Directors issue is a comprehensive listing of women executives, influencers and achievers contributing leadership to corporate boards. WomenInc.'s winter issue is available nationwide as of December 20, 2019... READ MORE

​​​Portfolio News

May 7, 2019

UCSF Rosenman Institute - Preventing Brain Cancer Recurrence with GammaTiles


Tempe, Arizona –Listen to The Health Technology podcast from UCSF Rosenman Institute to hear GT Medical Technologies, Inc. CEO Matt Likens share how GammaTile Therapy challenges the current standard of care for patients with recurrent brain tumors by improving quality of life and delaying time to recurrence for all tumor pathologies (gliomas, meningiomas, metastases, etc.). LISTEN HERE

​​​​Portfolio News

June 11, 2019

PBS, Arizona Horizon -  Implantable Brain Tumor Treatment


Tempe, Arizona – GT Medical Technologies has created a new way to target brain tumors like the type that took the late Senator John McCain’s life. GammaTile technology, invented and developed in Arizona, consists of four tiles implanted in a patient. These tiles contain dosages of radiation that targets glioblastomas. We’ll get more from Dr. David Brachman of GammaTile Technologies... WATCH HERE

​​​Portfolio News

June 17, 2019

GT Medical Technologies Announces Presentation of Data Demonstrating the Safety Profile of GammaTile Therapy for Various Brain Tumors​


Tempe, Arizona – GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the presentation of clinical data from a prospective study of GammaTile® Therapy in patients with previously irradiated intracranial neoplasms (brain tumors) at the American Brachytherapy Society (ABS) 2019 Annual Meeting in Miami. These data reinforce the safety profile of GammaTile Therapy, a surgically targeted radiation therapy (STaRT) that is designed to delay tumor regrowth for patients with recurrent intracranial neoplasms (brain tumors)... READ MORE

BlueStone News

​​​Portfolio News

April 11, 2019

GT Medical Technologies Co-Founder to Receive Prestigious Rosenblum-Mahaley Clinical Research Award at 2019 American Association of Neurological Surgeons Annual Scientific Meeting


Tempe, Arizona & San Diego, California – BlueStone portfolio company GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that Peter Nakaji, M.D., GT MedTech’s co-founder and director of the Neurosurgery Residency Program at Barrow Neurological Institute in Phoenix, has been selected by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors to receive the Rosenblum-Mahaley Clinical Research Award. The award recognizes established investigators in neuro-oncology who present the best clinical study in the field and acknowledges innovative approaches that lead to improved patient outcomes and quality of life.  Previous winners of this prestigious award...  READ MORE

Portfolio News

February 14, 2019

Doctors at the University of Minnesota are the first in the country to use a breakthrough brain cancer treatment


Minneapolis, Minnesota –  It sounds like science fiction, but doctors at University of Minnesota Health are the first in the country to offer an implantable form of radiation to target brain cancer. The implant is called GammaTile Therapy and Linda Tinega was the first patient in Minnesota to receive it.  "Each tile, has four, radioactive seeds on it," said Tinega, who had five GammaTiles implanted during surgery to remove a cancerous brain tumor two weeks ago. "Health-wise and stuff, it's not even like they're in there. I can't feel them." But her doctors say the tiles are already working, targeting the area where her tumor is most likely to regrow. "By implanting radiation directly, at the time of surgery, you are treating the tumor immediately," said Dr. Clark Chen, Head of the Department of Neurosurgery at...  READ MORE

BlueStone News

May 9, 2019

The Creative City Show - Venture Capital and the Innovation Ecosystem in Tucson


Tucson, Arizona –  Mara and Andrew join The Creative City Show host Zach Yentzer for a conversation on venture capital, the innovation ecosystem in Tucson, and the 4th industrial revolution. LISTEN HERE

BlueStone News

May 31, 2019

BLUESTONE DIRECTOR, ANDREW MORE, RECOGNIZED AS A 2019 EMERGING LEADER BY THE M&A ADVISOR
​​

Tucson, AZ, May 31, 2019 - Recently, The M&A Advisor announced the winners of the 2019 Emerging Leaders Awards. The M&A Advisor, renowned globally for its recognition of leading M&A, financing and turnaround professionals, created this event to promote mentorship and professional development amongst the emerging business leaders. Andrew More has been chosen for his accomplishments and expertise from a pool of nominees by an independent judging panel of distinguished business leaders... READ MORE

​​​Portfolio News

April 11, 2019

GT Medical Technologies Co-Founder to Receive Prestigious Rosenblum-Mahaley Clinical Research Award at 2019 American Association of Neurological Surgeons Annual Scientific Meeting


Tempe, Arizona & San Diego, California – BlueStone portfolio company GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced that Peter Nakaji, M.D., GT MedTech’s co-founder and director of the Neurosurgery Residency Program at Barrow Neurological Institute in Phoenix, has been selected by the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors to receive the Rosenblum-Mahaley Clinical Research Award. The award recognizes established investigators in neuro-oncology who present the best clinical study in the field and acknowledges innovative approaches that lead to improved patient outcomes and quality of life.  Previous winners of this prestigious award...  READ MORE

​​​​​Portfolio News

August 26, 2019

GT Medical Technologies, Inc. to be honored with an AZBio Fast Lane Award


Chandler, Arizona –The Arizona Bioindustry Association (AZBio) today announced that GT Medical Technologies, Inc. (GT MedTech) has been named an AZBio Fast Lane Company and will be honored on October 2, 2019 at the AZBio Awards. Approximately 400,000 Americans are newly diagnosed with some type of brain tumor each year. For decades, clinicians have sought better treatments for these patients that would effectively target tumor cells while preserving healthy tissue, but to no avail. There have been few new effective therapies over the past 30 years, and outcomes for patients have improved very little during this time. Recurrence of brain tumors is common, and about half of all patients treated for brain tumors have their disease recur within a year. As a result, patients often run out of treatment options when their tumors reoccur... READ MORE

​​​​​Portfolio News

August 15, 2019

GT Medical Technologies Announces Completion of First Case in Arizona to Use GammaTile Therapy


Scottsdale, Arizona & Tempe, Arizona – HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy™, a new approach to treating recurrent brain tumors. GammaTile Therapy is an FDA-cleared, surgically targeted radiation therapy (STaRT) that is designed to delay tumor regrowth for patients with all types of recurrent brain tumors. The first patient was treated by John Wanebo, M.D., a neurosurgeon and an independent member of the HonorHealth medical staff... READ MORE